

25 February 2026

ASX Announcement

Webcast Recording: H1 FY26 Investor Call

For shareholders and other interested parties who were unable to attend the H1 FY26 results presentation live, or would like the opportunity to view it again, the recording can be viewed at the link below.

<https://investors.polyново.com/webinars/6eW68y-h1-fy26-results-briefing>

- Chair update (timestamp 0:05)
- CEO update (timestamp 2:06)
- Financial results (timestamp 12:12)
- Q&A (timestamp 20:10)

This announcement has been authorised by PolyNovo Company Secretary, Amy Demediuk.

About PolyNovo[®]

PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb[®] polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see polyново.com

About NovoSorb[®] Technology

NovoSorb[®] is a proprietary biodegradable polymer platform designed to support tissue regeneration in complex wound care. The unique characteristics of NovoSorb[®] provide several key advantages including excellent biocompatibility, control over physical properties, a programmable bio-resorption profile and can be produced in many formats including film, fibre, foam, and coatings.

NovoSorb[®] BTM is a synthetic dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. This innovative product was the first to be commercially available utilising NovoSorb[®] technology and is supported by a growing body of independent clinical evidence.

NovoSorb[®] MTX is PolyNovo's latest advanced wound care product; a fully synthetic dermal matrix, developed in response to surgeon demand for a dermal substitute without a temporising, sealing membrane. Since receiving FDA 510(k) clearance in 2022, NovoSorb[®] MTX has rapidly gained surgeon adoption and is emerging as a key driver of growth.

